EBS FY 2011 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$422M

FY 2011 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$273M-4.5% YoY

Gross Profit

$231M84.6% margin

Operating Income

$32M11.7% margin

Net Income

$23M8.4% margin

EPS (Diluted)

$0.64

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

-$39M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$547M

Total Liabilities

$130M

Stockholders' Equity

$414M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$273M	$286M	-4.5%
Gross Profit	$231M	$239M	-3.3%
Operating Income	$32M	$74M	-56.4%
Net Income	$23M	$52M	-55.5%